拉米夫定预防鼻咽癌合并HBV阳性患者化疗中肝功能损害  

The effect of lamivudme in prevention of nasopharyngeal carcinoma with positive HBV chemotherapy for patients with liver function damage

作　　者：任庆[1] 熊锐华[1] 田秀荣[1] 唐新云[1] 林琳[1] 罗克品[1] 

机构地区：[1]中国人民解放军第181医院肿瘤科,广西桂林541002

出　　处：《现代肿瘤医学》2016年第3期383-386,共4页Journal of Modern Oncology

摘　　要：目的:探讨拉米夫定在预防鼻咽癌合并HBV阳性患者化疗中肝功能损害的作用。方法:84例经病理或细胞学证实,且经过HBV血清学检测确诊为HBs Ag阳性的鼻咽癌患者分为研究组(43例)与对照组(41例)。研究组化疗前预防性使用抗病毒药物拉米夫定,同期观察40例未患乙肝的患者。治疗后比较各组患者肝功能损害的情况以及对化疗的影响。结果:各组患者化疗后肝功能损害发生率分别为18.6%、39.0%、15.0%,差异有统计学意义。而且HBV发生再激活后DNA载量水平与肝功能损害程度之间高度相关。结论:HBs Ag阳性的鼻咽癌患者化疗后较HBs Ag阴性患者更容易出现肝功能损害,预防性使用抗病毒药物拉米夫定可明显降低HBV再激活肝炎的发生。Objective：To determine the role and value of lamivudine in prevention of nasopharyngeal carcinoma with positive HBV chemotherapy for patients with liver function damage. Methods ： A total of 84 nasopharyngeal carcinoma patients confirmed by histopathology or cytopathology with HBsAg- positive were divided into research group （43 cases） and control group（41 cases）. Patients of research group received prophylactic lamivudine before chemotherapy 40 patients without hepatitis B virus. Liver function were compared. Results ： Liver function damage in patients after chemotherapy were 18.6%, 39.0%, 15.0%, the difference was statistically significant. Conclusion： HBsAg - positive nasopharyngeal carcinoma patients were more likely to induce liver function damage after chemotherapy than HBsAg - negative patients. Prophylactic antivirus treatment with the uucleoside analog lamivudine can significantly reduce the occurrence of HBV - reactivated in nasopharyngeal carcinoma patients.

关 键 词：鼻咽癌 乙型肝炎病毒 化疗 肝功能损害 HBV再激活 

分 类 号：R739.63[医药卫生—肿瘤]